The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Prognostic Score for Advanced Hodgkin's Disease
Hasenclever, D., Diehl, V., Armitage, J. O., Assouline, D., Björkholm, M., Brusamolino, E., Canellos, G. P., Carde, P., Crowther, D., Cunningham, D., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392104 · Cited by 1,736
Lister, T. A., Crowther, D., Sutcliffe, S. B., Glatstein, E., Canellos, G. P., Young, R. C., Rosenberg, S. A., Coltman, C. A., & Tubiana, M. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1630 · Cited by 1,639
Linch, D. C., Goldstone, A. H., McMillan, A., Chopra, R., Vaughan Hudson, G., Winfield, D., Hancock, B., Moir, D., & Milligan, D. (1993) · The Lancet · doi:10.1016/0140-6736(93)92411-l · Cited by 1,051
A Handbook of Statistical Analyses Using SPSS
Landau, S., & Everitt, B. S. (2003) · Chapman & Hall/CRC eBooks · doi:10.1201/9780203009765 · Cited by 1,036
Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., Dörken, B., Müller-Hermelink, H.-K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022473 · Cited by 838
Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J., de Groot, T., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., & Verhoef, G. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf256 · Cited by 410
Mikhaeel, N. G., Hutchings, M., Fields, P. A., O'Doherty, M. J., & Timothy, A. R. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi272 · Cited by 401
Self-citationModelling Survival Data in Medical Research (2nd ed.) (Book)
Cowles, M. K. (2004) · Quarterly Publications of the American Statistical Association · Cited by 369
Mikhaeel, N. G., Timothy, A. R., O’Doherty, M. J., Hain, S. F., & Maisey, M. N. (2000) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190009113384 · Cited by 248
Self-citationSpecht, L., Gray, R. G., Clarke, M. J., & Peto, R. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.830 · Cited by 239
Jérusalem, G., Beguin, Y. P., Fassotte, M., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (2001) · PubMed · Cited by 218
Naumann, R., Vaic, A., Beuthien‐Baumann, B., Bredow, J., Kropp, J., Kittner, T., Franke, W., & Ehninger, G. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03147.x · Cited by 212
Jerusalem, G., Beguin, Y. P., Fassotte, M., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (2000) · PubMed · Cited by 203
Hodgkin's disease: Complications of therapy and excess mortality
Hoppe, R. T. (1997) · Annals of Oncology · doi:10.1093/annonc/8.suppl_1.s115 · Cited by 192
Long-term complications of treatment and causes of mortality after Hodgkin's disease
Hancock, S. L., & Hoppe, R. T. (1996) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(96)80018-x · Cited by 179
de Wit, M., Bumann, D., Beyer, W., Herbst, K., Clausen, M., & Hossfeld, D. K. (1997) · Annals of Oncology · doi:10.1093/annonc/8.suppl_1.s57 · Cited by 164
Lohri, A., Barnett, M., Fairey, R. N., O’Reilly, S., Phillips, G. L., Reece, D. E., Voss, N., & Connors, J. M. (1991) · Blood · doi:10.1182/blood.v77.10.2292.2292 · Cited by 132
Hoekstra, O. S., Ossenkoppele, G. J., Golding, R. P., van Lingen, A., Visser, G. W. M., Teule, G. J. J., & Huijgens, P. C. (1993) · PubMed · Cited by 108
Early therapy monitoring with FDG-PET in aggressive non-Hodgkin?s lymphoma and Hodgkin?s lymphoma
Torizuka, T., Nakamura, F., Kanno, T., Futatsubashi, M., Yoshikawa, E., Okada, H., Kobayashi, M., & Ouchi, Y. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1333-8 · Cited by 107
Staratschek‐Jox, A., Wolf, J., & Diehl, V. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46877-8_11 · Cited by 58
FDG-PET in the clinical management of Hodgkin lymphoma
Hutchings, M., Eigtved, A., & Specht, L. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.05.007 · Cited by 55
Self-citationCurrent therapies in Hodgkin's disease
Kogel, K. E., & Sweetenham, J. W. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1156-7 · Cited by 23
Cited by
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
“This is possibly similar to the ‘‘minimal residual uptake’’ category reported in treated lymphomas by Mikhaeel’s group (89,98).”
ResultBarrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S. P., Schwartz, L. H., Zucca, E., Fisher, R. I., Trotman, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5229 · Cited by 1,665
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6525 · Cited by 846
Self-citationResults of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma
Radford, J., Illidge, T., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., Wimperis, J., Culligan, D., Popova, B., Smith, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408648 · Cited by 762
Metadata
- Authors
- Hutchings, M., Mikhaeel, N. G., Fields, P. A., Nunan, T., & Timothy, A. R.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2005-07
- Volume
- 16
- Issue
- 7
- Pages
- 1160-1168
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2162340856
- Cited by
- 327
- References
- 22
- FWCI
- 12.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.